Evaluation of the effect of Allopurinol in reducing heart damage in acute ischemic heart patients
Phase 2
- Conditions
- Acute cardiac ischemic patients.Non-ST elevation (NSTEMI) myocardial infarctionI21.4
- Registration Number
- IRCT20111206008307N36
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients diagnosed with acute ischemic heart syndrome
Age 80-18 years
Ability to understand and sign consent forms
Exclusion Criteria
Serum creatinine above 2 milligram Per deciliter
Acute myocardial infraction
History of dialysis
Cardiogenic shock
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiac troponin I. Timepoint: Before, 8, 16, 24 and 32 hours after receiving allopurinol. Method of measurement: ELISA kits.;Creatine Kinase-MB. Timepoint: Before, 8, 16, 24 and 32 hours after receiving allopurinol. Method of measurement: ELISA kite.
- Secondary Outcome Measures
Name Time Method